Natco Pharma Ltd on Friday said it has received final approval from the US health regulator for its generic Tipiracil Hydrochloride and Trifluridine tablets indicated primarily for the treatment of colorectal cancer.

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

The US Food and Drug Administration (USFDA) granted final approval to the abbreviated new drug application (ANDA) for Tipiracil Hydrochloride and Trifluridine Tablets, the generic version of Lonsurf sold in the US by Taiho Oncology Inc, Natco said in a regulatory filing.

"Natco believes it is one of the first-to-file for the product and may be eligible for a 180-day exclusivity at the time of launch," it added.

Lonsurf had generated annual sales of USD 211 million in the US during the 12-month period ended December 2022, the company said citing IQVIA data.

Catch latest stock market updates here. For all other news related to business, politics, tech, sports and auto, visit Zeebiz.com.